DENTSPLY SIRONA Inc. (NASDAQ:XRAY) saw unusually large options trading on Friday. Investors bought 3,416 put options on the company. This represents an increase of approximately Infinity compared to the average daily volume of 0 put options.
In other DENTSPLY SIRONA news, insider Mark Thierer purchased 77,000 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The stock was purchased at an average cost of $66.04 per share, with a total value of $5,085,080.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Nicholas W. Alexos bought 50,000 shares of the stock in a transaction dated Monday, November 13th. The stock was purchased at an average cost of $65.85 per share, with a total value of $3,292,500.00. The disclosure for this purchase can be found here. 1.99% of the stock is currently owned by company insiders.
A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in DENTSPLY SIRONA by 2.5% during the 2nd quarter. Vanguard Group Inc. now owns 22,728,062 shares of the medical instruments supplier’s stock worth $1,473,688,000 after acquiring an additional 562,993 shares during the period. Ruane Cunniff & Goldfarb Inc. boosted its position in shares of DENTSPLY SIRONA by 0.5% during the 3rd quarter. Ruane Cunniff & Goldfarb Inc. now owns 8,890,655 shares of the medical instruments supplier’s stock worth $531,750,000 after purchasing an additional 40,767 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of DENTSPLY SIRONA by 6.7% during the 3rd quarter. Principal Financial Group Inc. now owns 6,910,770 shares of the medical instruments supplier’s stock worth $413,333,000 after purchasing an additional 436,338 shares in the last quarter. Jackson Square Partners LLC boosted its position in shares of DENTSPLY SIRONA by 15.6% during the 3rd quarter. Jackson Square Partners LLC now owns 6,334,906 shares of the medical instruments supplier’s stock worth $378,890,000 after purchasing an additional 855,199 shares in the last quarter. Finally, Veritas Asset Management LLP boosted its position in shares of DENTSPLY SIRONA by 2.6% during the 2nd quarter. Veritas Asset Management LLP now owns 6,201,155 shares of the medical instruments supplier’s stock worth $402,083,000 after purchasing an additional 157,616 shares in the last quarter. Hedge funds and other institutional investors own 94.65% of the company’s stock.
Shares of DENTSPLY SIRONA (NASDAQ:XRAY) opened at $65.39 on Wednesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.32 and a quick ratio of 1.59. The stock has a market capitalization of $15,113.13, a P/E ratio of 26.22, a P/E/G ratio of 2.60 and a beta of 1.27. DENTSPLY SIRONA has a 12 month low of $52.53 and a 12 month high of $67.95.
DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Friday, November 3rd. The medical instruments supplier reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.04. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $978.99 million. DENTSPLY SIRONA had a positive return on equity of 7.56% and a negative net margin of 20.33%. The company’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.66 earnings per share. research analysts predict that DENTSPLY SIRONA will post 2.66 EPS for the current year.
A number of brokerages recently commented on XRAY. HC Wainwright reaffirmed a “buy” rating and set a $68.00 price objective (down from $74.00) on shares of DENTSPLY SIRONA in a research note on Monday, August 14th. Barrington Research upgraded DENTSPLY SIRONA from a “market perform” rating to an “outperform” rating and set a $73.00 target price on the stock in a report on Monday, November 6th. Morgan Stanley reiterated an “overweight” rating and set a $69.00 target price (up from $67.00) on shares of DENTSPLY SIRONA in a report on Friday, October 6th. BidaskClub lowered DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Finally, TheStreet lowered DENTSPLY SIRONA from a “b” rating to a “c+” rating in a report on Wednesday, August 9th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. DENTSPLY SIRONA currently has an average rating of “Hold” and an average price target of $67.00.
DENTSPLY SIRONA Company Profile
DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.
Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.